Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.72 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.52 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.52 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | RXRA | P19793 | 2/20 | 0.47 |
| ▸ | RXRB | P28702 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ESRRG | P62508 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7218374 | 0.85 | ACHE (0.72) | ACHECYP26A1CYP26B1NR1H4HDAC8 | |
| SCHEMBL11749643 | 0.84 | ACHE (0.70) | ACHECYP26A1CYP26B1NR1H4HDAC8 | |
| Methane SCHEMBL377242 | 0.84 | ACHE (0.70) | ACHECYP26A1CYP26B1NR1H4HDAC8 | |
| SCHEMBL30479628 | 0.84 | ACHE (0.70) | ACHECYP26A1CYP26B1NR1H4HDAC8 | |
| SCHEMBL28551872 | 0.83 | ACHE (0.51) | ACHECYP26A1CYP26B1NR1H4CES2 | |
| SCHEMBL16775747 | 0.82 | ACHE (0.68) | ACHECYP26A1CYP26B1NR1H4HDAC8 | |
| SCHEMBL1712437 | 0.81 | CES2 (0.67) | ACHECES2MEN1KMT2AALDH1A1 | |
| SCHEMBL4075763 | 0.80 | ACHE (0.46) | ACHEHDAC8HDAC6RXRARXRB | |
| SCHEMBL12235278 | 0.80 | TDP1 (0.48) | ACHEMEN1KMT2ASMN1; SMN2NPC1 | |
| SCHEMBL16958055 | 0.79 | ACHE (0.54) | ACHECYP26A1CYP26B1NR1H4HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106542996-B | A kind of synthetic method of 2- hydroxy-3-nitroacetophenone | 昆山力田医化科技有限公司 | 2019-08-30 | — | — | CN | claimed |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | AMGEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| CN-106542996-B | A kind of synthetic method of 2- hydroxy-3-nitroacetophenone | 昆山力田医化科技有限公司 | 2019-08-30 | — | — | CN | disclosed |
| US-20180222895-A1 | COMPOUNDS FOR USE IN PREPARING HETEROCYCLIC TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2018-08-09 | — | — | US | disclosed |
| US-9988369-B2 | Heterocyclic triazole compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2018-06-05 | — | — | US | disclosed |
| US-9868721-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9845310-B2 | Intermediates for preparing triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170320860-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-11-09 | — | — | US | disclosed |
| US-20170281625-A1 | METHODS OF TREATING HEART FAILURE | AMGEN INC. | 2017-10-05 | — | — | US | disclosed |
| US-9751864-B2 | Methods for preparing triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-20170042897-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170044131-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-16 | — | — | US | disclosed |
| US-20170035744-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170037026-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2017-02-09 | — | — | US | disclosed |
| US-20160340336-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. | 2016-11-24 | — | — | US | disclosed |
| EP-0716088-B1 | PROCESS FOR PRODUCING 2-(TETRAZOL-5-YL)-4-OXO-4H-BENZOPYRANS | SUMITOMO CHEMICAL CO (JP) | 2004-02-18 | — | — | EP | disclosed |
| US-5597929-A | Production process of 2-(tetrazol-5-yl)-4-oxo-4H-benzopyran | SUMITOMO CHEMICAL CO., LTD. (JP) | 1997-01-28 | — | — | US | disclosed |
| EP-0716088-A1 | PROCESS FOR PRODUCING 2-(TETRAZOL-5-YL)-4-OXO-4H-BENZOPYRANS | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1996-06-12 | — | — | EP | disclosed |
| US-4745114-A | MORPHOLINE SUBSTITUTED BENZOPYRAN | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-05-17 | — | — | US | disclosed |
| WO-1980000561-A1 | ALPHA-ALKYL-O-OXY-BENZYLAMIN DERIVATIVES,PREPARATION THEREOF AND REMEDIES CONTAINING THEM | SANDOZ AG (CH) | 1980-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044131-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | ACHE 4306/4885CYP26A1 296/4885CYP26B1 350/4885 |
| US-20180222895-A1 | COMPOUNDS FOR USE IN PREPARING HETEROCYCLIC TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, APLNR, GPR27 | ACHE 4483/4885CYP26A1 930/4885CYP26B1 826/4885 |
| US-20170037026-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | ACHE 4306/4885CYP26A1 296/4885CYP26B1 350/4885 |
| US-20170281625-A1 | METHODS OF TREATING HEART FAILURE | FABP3, TNNI3, APLNR | ACHE 2361/4885CYP26A1 2127/4885CYP26B1 1806/4885 |
| US-20170320860-A1 | HETEROCYCLIC TRIAZOLE COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | TBXA2R, APLNR, AGTR1 | ACHE 4385/4885CYP26A1 699/4885CYP26B1 650/4885 |
| US-20170042897-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | ACHE 4306/4885CYP26A1 296/4885CYP26B1 350/4885 |
| US-20160340336-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | ACHE 4306/4885CYP26A1 296/4885CYP26B1 350/4885 |
| US-20170035744-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | ACHE 4306/4885CYP26A1 296/4885CYP26B1 350/4885 |
| US-11807624-B2 | Substituted pyrimidinones as agonists of the APJ receptor | APLNR, AGTR1, AGTR2 | ACHE 4793/4885CYP26A1 658/4885CYP26B1 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.